Gillis Jonathan: insider trades.
Gillis Jonathan reported 9 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 7 sales ($1.4M), across 1 company.
- Transactions
- 9
- Purchases (P)
- 0
- Sales (S)
- 7
- Companies
- 1
- Name as filed
- GILLIS JONATHAN
Companies
| Company | Relationship | Transactions |
|---|---|---|
| MapLight Therapeutics, Inc. (MPLT) | Officer · CAO and Interim CFO | 9 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-17 | MapLight Therapeutics, Inc. | A | 6,020 | $0 | 150,260 | Form 4 |
| 2026-08-17 | MapLight Therapeutics, Inc. | A | 2,222 | $0 | 152,482 | Form 4 |
| 2026-07-17 | MapLight Therapeutics, Inc. | S | 600 | $36.51 | 162,109 | Form 4 |
| 2026-07-17 | MapLight Therapeutics, Inc. | S | 16,969 | $37.61 | 145,140 | Form 4 |
| 2026-07-17 | MapLight Therapeutics, Inc. | S | 900 | $38.17 | 144,240 | Form 4 |
| 2026-07-16 | MapLight Therapeutics, Inc. | S | 6,979 | $36.66 | 164,185 | Form 4 |
| 2026-07-16 | MapLight Therapeutics, Inc. | S | 1,476 | $37.44 | 162,709 | Form 4 |
| 2026-07-15 | MapLight Therapeutics, Inc. | S | 5,356 | $36.13 | 175,863 | Form 4 |
| 2026-07-15 | MapLight Therapeutics, Inc. | S | 4,699 | $36.94 | 171,164 | Form 4 |
Questions
What stock did Gillis Jonathan buy or sell?
Gillis Jonathan reported 9 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 7 sales ($1.4M), across 1 company.
Is Gillis Jonathan the same person as other filers with this name?
This page covers SEC CIK 1709954 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/gillis-jonathan-1709954.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.